Mathias Zink
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mathias Zink has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Fritz A. Henn
Central Institute of Mental Health, Mannheim, Germany
7 shared publications- Andrea Schmitt
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany
4 shared publications Johannes Thome
Department of Psychiatry, University of Wales Swansea, Swansea, UK
3 shared publications- Alexander Sartorius
Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
2 shared publications F. A. Henn
2 shared publicationsH. Dressing
Klinik für Psychiatrie und Psychotherapie
2 shared publications
Latest Publications
- 1 September 2005
- Published by Springer Nature in Der Nervenarzt
- Vol. 76 (9) , 1092-1102
Clozapin-Augmentation mit atypischen Antipsychotika
- 1 September 2005
- Published by Springer Nature in Der Nervenarzt
- Vol. 76 (9) , 1092-1102
Clozapin-Augmentation mit atypischen Antipsychotika
- 28 June 2005
- Published by Springer Nature in Psychopharmacology
- Vol. 181 (3) , 560-565
Antidepressants differentially affect expression of complexin I and II RNA in rat hippocampus
Disturbance of synaptic transmission is currently viewed as an important pathophysiological mechanism and therapeutic target of mood disorders. Amongst other lines of evidence this theory is based on human post-mortem investigations showing differential expression of complexins. In order to discriminate between molecular correlates of the disease itself and effects of psychotropic drugs given to patients, we performed an animal trial using subchronic antidepressant treatment. Cohorts of adult male Sprague–Dawley rats were treated over a period of 14 days with intraperitoneal injections of either saline (0.9%, n=8), desipramine (15 mg/kg, n=7), fluoxetine (10 mg/kg, n=8), or tranylcypromine (10 mg/kg, n=5). Brain slices were used for in situ hybridizations with 35S labelled RNA probes of the genes complexin I, complexin II and syntaxin 1 A, the SNARE complex protein interacting with the complexins, and assessed semi-quantitatively for region-specific expression levels. Expression of complexin I was induced only in habenular nuclei after treatment with fluoxetine. In contrast, complexin II was significantly induced by desipramine and tranylcypromine, but not fluoxetine, in several brain regions. All treatment groups, but most significantly fluoxetine-treated animals, showed higher expression levels of syntaxin 1A. Antidepressants differentially affect expression levels of complexin I and more prominently complexin II and syntaxin 1A. The induction of complexin II and syntaxin 1A might strengthen the synaptic transmission at axo-dendritic or axo-axonal synapses. Previous post-mortem findings reporting on downregulation of complexins cannot be explained as mere effects of psychotropic drug treatment.
- 28 June 2005
- Published by Springer Nature in Psychopharmacology
- Vol. 181 (3) , 560-565
Antidepressants differentially affect expression of complexin I and II RNA in rat hippocampus
Disturbance of synaptic transmission is currently viewed as an important pathophysiological mechanism and therapeutic target of mood disorders. Amongst other lines of evidence this theory is based on human post-mortem investigations showing differential expression of complexins. In order to discriminate between molecular correlates of the disease itself and effects of psychotropic drugs given to patients, we performed an animal trial using subchronic antidepressant treatment. Cohorts of adult male Sprague–Dawley rats were treated over a period of 14 days with intraperitoneal injections of either saline (0.9%, n=8), desipramine (15 mg/kg, n=7), fluoxetine (10 mg/kg, n=8), or tranylcypromine (10 mg/kg, n=5). Brain slices were used for in situ hybridizations with 35S labelled RNA probes of the genes complexin I, complexin II and syntaxin 1 A, the SNARE complex protein interacting with the complexins, and assessed semi-quantitatively for region-specific expression levels. Expression of complexin I was induced only in habenular nuclei after treatment with fluoxetine. In contrast, complexin II was significantly induced by desipramine and tranylcypromine, but not fluoxetine, in several brain regions. All treatment groups, but most significantly fluoxetine-treated animals, showed higher expression levels of syntaxin 1A. Antidepressants differentially affect expression levels of complexin I and more prominently complexin II and syntaxin 1A. The induction of complexin II and syntaxin 1A might strengthen the synaptic transmission at axo-dendritic or axo-axonal synapses. Previous post-mortem findings reporting on downregulation of complexins cannot be explained as mere effects of psychotropic drug treatment.
- 1 March 2005
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 16 (4) , 377-380
Ethanol induces GAD67 and VGAT in slice cultures of newborn rat cerebral cortex
Exposure of the developing brain to ethanol disposes to the fetal alcohol syndrome, causing changes in the neurotransmitter systems of glutamate and γ-amino butyric acid (GABA). However, expression of genes involved in GABA synthesis, vesicular and transmembrane transport has not been investigated so far. We exposed organotypic slice cultures of newborn rat cerebral cortex to ethanol (100 mM) for 4 days and observed a significant induction of the enzyme producing GABA (GAD67, +21%) and the vesicular transporter VGAT (+112%), whereas the expression of the transmembrane transporters did not differ from control conditions. In summary, ethanol exposure of the developing cortex induces GABAergic genes, which might facilitate the excitatory functions of GABA during development.
- 1 March 2005
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 16 (4) , 377-380
Ethanol induces GAD67 and VGAT in slice cultures of newborn rat cerebral cortex
Exposure of the developing brain to ethanol disposes to the fetal alcohol syndrome, causing changes in the neurotransmitter systems of glutamate and γ-amino butyric acid (GABA). However, expression of genes involved in GABA synthesis, vesicular and transmembrane transport has not been investigated so far. We exposed organotypic slice cultures of newborn rat cerebral cortex to ethanol (100 mM) for 4 days and observed a significant induction of the enzyme producing GABA (GAD67, +21%) and the vesicular transporter VGAT (+112%), whereas the expression of the transmembrane transporters did not differ from control conditions. In summary, ethanol exposure of the developing cortex induces GABAergic genes, which might facilitate the excitatory functions of GABA during development.
- 1 November 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (11) , 1752-1757
Ethanol Induces Expression of the Glutamate Transporters EAAT1 and EAAT2 in Organotypic Cortical Slice Cultures
Background: Exposure of the developing brain to ethanol disposes the fetus to fetal alcohol syndrome and causes a number of changes in several neurochemical systems. In particular, the glutamatergic system is affected by ethanol. Thus, increased sensitivity of glutamate receptors and enhanced transmembrane transport of glutamate were found in primary astrocyte cultures. However, in these in vitro studies, changes in the expression of glutamate transporters were not detected. To further characterize the influence of chronic ethanol exposure on the developing brain, we assessed the transcriptional and translational regulation of glutamate transporters in a less artificial in vitro system. Methods: We exposed postnatal rat cortical organotypic slice cultures to ethanol (100 mM) for 4 and 8 days. Expression of the excitatory amino acid transporters EAAT1 and EAAT2 was analyzed in comparison to untreated controls with semiquantitative reverse transcriptase‐polymerase chain reaction. In addition, changes in protein expression were detected by Western blotting. Results: In ethanol‐exposed cortical slices, we observed more prominent fiber outgrowth and significantly increased gene expression (EAAT1: +35%, p= 0.029; EAAT2: +251%, p= 0.015). These findings could be verified on the protein level, because Western blot analysis revealed significantly higher levels of EAAT1 (+76%; p= 0.008) and EAAT2 (+104%; p= 0.018) in ethanol‐treated slices compared with controls. Conclusions: Our results are in concert with earlier studies describing the induction of glutamate transport by ethanol. Enhanced expression of EAAT1 and EAAT2 after ethanol exposure can be viewed as a maladaptive process that disposes the developing brain to fetal alcohol syndrome.
- 1 November 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (11) , 1752-1757
Ethanol Induces Expression of the Glutamate Transporters EAAT1 and EAAT2 in Organotypic Cortical Slice Cultures
Background: Exposure of the developing brain to ethanol disposes the fetus to fetal alcohol syndrome and causes a number of changes in several neurochemical systems. In particular, the glutamatergic system is affected by ethanol. Thus, increased sensitivity of glutamate receptors and enhanced transmembrane transport of glutamate were found in primary astrocyte cultures. However, in these in vitro studies, changes in the expression of glutamate transporters were not detected. To further characterize the influence of chronic ethanol exposure on the developing brain, we assessed the transcriptional and translational regulation of glutamate transporters in a less artificial in vitro system. Methods: We exposed postnatal rat cortical organotypic slice cultures to ethanol (100 mM) for 4 and 8 days. Expression of the excitatory amino acid transporters EAAT1 and EAAT2 was analyzed in comparison to untreated controls with semiquantitative reverse transcriptase‐polymerase chain reaction. In addition, changes in protein expression were detected by Western blotting. Results: In ethanol‐exposed cortical slices, we observed more prominent fiber outgrowth and significantly increased gene expression (EAAT1: +35%, p= 0.029; EAAT2: +251%, p= 0.015). These findings could be verified on the protein level, because Western blot analysis revealed significantly higher levels of EAAT1 (+76%; p= 0.008) and EAAT2 (+104%; p= 0.018) in ethanol‐treated slices compared with controls. Conclusions: Our results are in concert with earlier studies describing the induction of glutamate transport by ethanol. Enhanced expression of EAAT1 and EAAT2 after ethanol exposure can be viewed as a maladaptive process that disposes the developing brain to fetal alcohol syndrome.
- 1 August 2004
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 19 (5) , 320-321
Remission of polydipsia as antipsychotic effect of clozapine
- 1 August 2004
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 19 (5) , 320-321
Remission of polydipsia as antipsychotic effect of clozapine
- 8 July 2004
- Published by Georg Thieme Verlag KG in Psychiatrische Praxis
- Vol. 31 (5) , 259-261
Augmentation von Clozapin mit Ziprasidon
Hintergrund: In Fällen therapieresistenter Schizophrenie werden zunehmend oft atypische Antipsychotika kombiniert. Methodik: Wir berichten über einen schizophrenen Patienten, dessen Erkrankung sich gegenüber Olanzapin, Risperidon und Quetiapin resistent erwies, unter Clozapin aber teilremittierte. Weil Nebenwirkungen die Zuverlässigkeit der Einnahme gefährdeten, wurde mit Ziprasidon augmentiert. Ergebnisse: Positiv- und Negativsymptomatik wurden gut kontrolliert, trotz einer transienten Hyperprolaktinämie war die subjektive Zufriedenheit sehr hoch. Diskussion: Die berichtete Kombinationsbehandlung erscheint neurobiologisch sinnvoll, kann Nebenwirkungen reduzieren und sollte hinsichtlich Nutzen und Risiken mit prospektiven Studien untersucht werden. Objectives: In cases of treatment-resistant schizophrenic psychoses combined application of atypical antipsychotic drugs is an often-used strategy. Method: We report the case of a 35-year old man with paranoid schizophrenia, whose symptoms turned out to be resistant to the application of olanzapine, risperidone and quetiapine. After switch to clozapine paranoid delusions remitted, but schizophrenic negative symptoms persisted and side effects limited the patient's compliance. Augmentation with ziprasidone allowed a reduction of the clozapine dose and ameliorated the affective deficits. Results: Positive and negative symptoms were well controlled. In spite of a transient hyperprolactinaemia and sexual dysfunction the patient was highly content. Discussion: The combined application of ziprasidone and clozapine follows a neurobiological rationale, seems able to reduce side effects, and should be further evaluated with respect to risk and benefit in prospective studies.
- 8 July 2004
- Published by Georg Thieme Verlag KG in Psychiatrische Praxis
- Vol. 31 (5) , 259-261
Augmentation von Clozapin mit Ziprasidon
Hintergrund: In Fällen therapieresistenter Schizophrenie werden zunehmend oft atypische Antipsychotika kombiniert. Methodik: Wir berichten über einen schizophrenen Patienten, dessen Erkrankung sich gegenüber Olanzapin, Risperidon und Quetiapin resistent erwies, unter Clozapin aber teilremittierte. Weil Nebenwirkungen die Zuverlässigkeit der Einnahme gefährdeten, wurde mit Ziprasidon augmentiert. Ergebnisse: Positiv- und Negativsymptomatik wurden gut kontrolliert, trotz einer transienten Hyperprolaktinämie war die subjektive Zufriedenheit sehr hoch. Diskussion: Die berichtete Kombinationsbehandlung erscheint neurobiologisch sinnvoll, kann Nebenwirkungen reduzieren und sollte hinsichtlich Nutzen und Risiken mit prospektiven Studien untersucht werden. Objectives: In cases of treatment-resistant schizophrenic psychoses combined application of atypical antipsychotic drugs is an often-used strategy. Method: We report the case of a 35-year old man with paranoid schizophrenia, whose symptoms turned out to be resistant to the application of olanzapine, risperidone and quetiapine. After switch to clozapine paranoid delusions remitted, but schizophrenic negative symptoms persisted and side effects limited the patient's compliance. Augmentation with ziprasidone allowed a reduction of the clozapine dose and ameliorated the affective deficits. Results: Positive and negative symptoms were well controlled. In spite of a transient hyperprolactinaemia and sexual dysfunction the patient was highly content. Discussion: The combined application of ziprasidone and clozapine follows a neurobiological rationale, seems able to reduce side effects, and should be further evaluated with respect to risk and benefit in prospective studies.
- 1 July 2004
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 37 (4) , 171-174
Differential Effects of Long-Term Treatment with Clozapine or Haloperidol on GABA Transporter Expression
Background: Post-mortem studies with brain samples of schizophrenic patients led revealed altered GABA-ergic markers like reduced expression of the GABA transporter GAT-1. Whether this effect is due to the pathophysiology of schizophrenia or to antipsychotic treatment has not been investigated. We therefore established an animal trial of long-term antipsychotic treatment to address this question. Methods: A total of 33 adult male rats were investigated in three cohorts of 11 animals. One group received clozapine (45 mg/kg/day), another group haloperidol (1.5 mg/kg/day), and the third one pH-adapted water over a period of 6 months. In situ hybridization with cRNA probes specific for GABA transporters VGAT, GAT-1 and GAT-3 were performed in comparison to control animals. Results: While GAT-1 was upregulated, VGAT expression declined in cortical and limbic brain regions, whereby haloperidol showed a greater effect than clozapine. GAT-3 expression was suppressed in parietal and temporal cortex. Conclusions: We thus conclude that long-term antipsychotic treatment alters GABA transporter expression in rat. The upregulation of GAT-1 contrasts with the post-mortem finding of reduced GAT-1 expression in schizophrenic patients. Our results facilitate the distinction between disease dependent changes of GABAergic markers and medication effects.
- 1 July 2004
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 37 (4) , 171-174
Differential Effects of Long-Term Treatment with Clozapine or Haloperidol on GABA Transporter Expression
Background: Post-mortem studies with brain samples of schizophrenic patients led revealed altered GABA-ergic markers like reduced expression of the GABA transporter GAT-1. Whether this effect is due to the pathophysiology of schizophrenia or to antipsychotic treatment has not been investigated. We therefore established an animal trial of long-term antipsychotic treatment to address this question. Methods: A total of 33 adult male rats were investigated in three cohorts of 11 animals. One group received clozapine (45 mg/kg/day), another group haloperidol (1.5 mg/kg/day), and the third one pH-adapted water over a period of 6 months. In situ hybridization with cRNA probes specific for GABA transporters VGAT, GAT-1 and GAT-3 were performed in comparison to control animals. Results: While GAT-1 was upregulated, VGAT expression declined in cortical and limbic brain regions, whereby haloperidol showed a greater effect than clozapine. GAT-3 expression was suppressed in parietal and temporal cortex. Conclusions: We thus conclude that long-term antipsychotic treatment alters GABA transporter expression in rat. The upregulation of GAT-1 contrasts with the post-mortem finding of reduced GAT-1 expression in schizophrenic patients. Our results facilitate the distinction between disease dependent changes of GABAergic markers and medication effects.
- 30 June 2004
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 111 (12) , 1537-1542
Differential expression of glutamate transporters EAAT1 and EAAT2 in mice deficient for PACAP-type I receptor
Pituitary adenylate cyclase-activating polypeptide (PACAP) modulates glutamatergic neurotransmission and induces the expression of glutamate transporters EAAT1 and EAAT2 in newborn mouse astroglial cell cultures. Since nanomolar concentrations of PACAP exert this effect, signal transduction via the high affinity PACAP-type I-receptor PAC1 was assumed. To test this hypothesis and to assess the importance of PAC1-signalling in vivo, we analyzed glutamate transporter expression in mice with a PAC1 knockout. EAAT1 and EAAT2 expression was investigated in the hippocampus and the cerebral cortex of PAC1 mutant mice and wildtype littermates by semiquantitative in-situ-hybridization. PAC1-knockout mice show a subtle but significant reduction of EAAT1 expression in the dentate gyrus. In contrast, reduced expression levels of EAAT1 in the cerebral cortex did not reach statistical significance and EAAT2 expression was unchanged in CA3 and cerebral cortex of PAC1 mutant mice. Our data confirm the previously reported in-vitro-regulation of EAAT1 in the adult nervous system in vivo. EAAT2 expression, however, is unchanged in PAC1 knockout mice, most likely due to counterbalancing factors.
- 30 June 2004
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 111 (12) , 1537-1542
Differential expression of glutamate transporters EAAT1 and EAAT2 in mice deficient for PACAP-type I receptor
Pituitary adenylate cyclase-activating polypeptide (PACAP) modulates glutamatergic neurotransmission and induces the expression of glutamate transporters EAAT1 and EAAT2 in newborn mouse astroglial cell cultures. Since nanomolar concentrations of PACAP exert this effect, signal transduction via the high affinity PACAP-type I-receptor PAC1 was assumed. To test this hypothesis and to assess the importance of PAC1-signalling in vivo, we analyzed glutamate transporter expression in mice with a PAC1 knockout. EAAT1 and EAAT2 expression was investigated in the hippocampus and the cerebral cortex of PAC1 mutant mice and wildtype littermates by semiquantitative in-situ-hybridization. PAC1-knockout mice show a subtle but significant reduction of EAAT1 expression in the dentate gyrus. In contrast, reduced expression levels of EAAT1 in the cerebral cortex did not reach statistical significance and EAAT2 expression was unchanged in CA3 and cerebral cortex of PAC1 mutant mice. Our data confirm the previously reported in-vitro-regulation of EAAT1 in the adult nervous system in vivo. EAAT2 expression, however, is unchanged in PAC1 knockout mice, most likely due to counterbalancing factors.
- 1 April 2004
- Published by Elsevier in Neuroscience Letters
- Vol. 360 (1-2) , 106-108
Reduced expression of brain-derived neurotrophic factor in mice deficient for pituitary adenylate cyclase activating polypeptide type-I-receptor
- 1 April 2004
- Published by Elsevier in Neuroscience Letters
- Vol. 360 (1-2) , 106-108
Reduced expression of brain-derived neurotrophic factor in mice deficient for pituitary adenylate cyclase activating polypeptide type-I-receptor
- 16 March 2004
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 19 (4) , 271-273
Combination of ziprasidone and clozapine in treatment‐resistant schizophrenia
In cases of treatment‐resistant schizophrenia the combined application of antipsychotic drugs often becomes necessary. Clozapine has been combined successfully with other atypical antipsychotic drugs such as risperidone or amisulpride in the past.We report the difficult treatment of a 28‐year‐old schizophrenic woman. Psychotic symptoms were found resistant to monotherapy with clozapine or ziprasidone. In contrast, combined application led to a marked improvement in both positive and negative symptoms of schizophrenia along with a decrease of side effects.The reported combination is a promising option in cases of treatment‐resistant schizophrenia and should be further evaluated in prospective studies. Copyright © 2004 John Wiley & Sons, Ltd.
- 16 March 2004
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 19 (4) , 271-273
Combination of ziprasidone and clozapine in treatment‐resistant schizophrenia
In cases of treatment‐resistant schizophrenia the combined application of antipsychotic drugs often becomes necessary. Clozapine has been combined successfully with other atypical antipsychotic drugs such as risperidone or amisulpride in the past.We report the difficult treatment of a 28‐year‐old schizophrenic woman. Psychotic symptoms were found resistant to monotherapy with clozapine or ziprasidone. In contrast, combined application led to a marked improvement in both positive and negative symptoms of schizophrenia along with a decrease of side effects.The reported combination is a promising option in cases of treatment‐resistant schizophrenia and should be further evaluated in prospective studies. Copyright © 2004 John Wiley & Sons, Ltd.